Hims & Hers Health Inc. Aktie News

The FDA said “decisive steps” will be taken to restrict drugs using GLP-1 active pharmaceutical ingredients in non-approved drugs.

Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to better healthcare.

Risk-off sentiment is driving sharp sell-offs in Bitcoin and major software stocks, with investors reallocating away from stretched tech valuations. AI-driven CapEx arms race at Alphabet (GOOGL) and Amazon (AMZN) is sparking concerns about profitability and sector disruption, despite strong revenue growth.

Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking debate about the legality of the move and threatening drugmaker returns in the burgeoning U.S. cash-pay market.

Shares in the Danish drugmaker have tanked this week, dragged down by a weak sales outlook and the launch of a Wegovy knockoff.

Online telehealth company Hims & Hers stock fell Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action. Hims is launching its pill for as little as $49, significantly lower than the $149 Novo sells the branded pill for.

Novo Nordisk shares rallied on Friday in what's still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug.

Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its announcement of a weight-loss pill with a $49-a-month introductory price. Its shares ended down anyway.